Plain-English translation of NCT07646860 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing , a new medication given by injection, in Japanese children ages 1 to 18 who have pulmonary arterial hypertension (PAH)—a serious condition where blood vessels in the lungs become too narrow and stiff. Researchers want to learn whether this medication is safe, how well children tolerate it, and whether it helps reduce the pressure and resistance in those lung blood vessels. Children will continue their regular PAH treatments while also receiving this new medication.
Pulmonary arterial hypertension is a rare but serious condition in children that can limit their activity and quality of life. This trial exists to see if this medication can help reduce the strain on children's lungs and hearts when used together with standard treatments.
You likely qualify if…
You likely don't qualify if…
If you join this study, your child will receive injections of the new medication under the skin every 3 weeks for about 24 weeks, starting at a lower dose and potentially increasing to a higher dose after 6 weeks. Your child will continue taking all their regular PAH medications during this time. The study involves regular check-ups where doctors will monitor safety, take blood samples, and assess how your child's lungs are responding. After the initial 24 weeks, children who are doing well may have the option to continue receiving the medication for up to an additional 4 years.
AI-generated summary from trial data · Aug 21, 2026 · Not medical advice
Japan